Cargando…
CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression
Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Surprisingl...
Autores principales: | Das, Amlan, Haque, Inamul, Ray, Priyanka, Ghosh, Arnab, Dutta, Debasmita, Quadir, Mohiuddin, De, Archana, Gunewardena, Sumedha, Chatterjee, Indranil, Banerjee, Snigdha, Weir, Scott, Banerjee, Sushanta K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981588/ https://www.ncbi.nlm.nih.gov/pubmed/33745223 http://dx.doi.org/10.1002/prp2.753 |
Ejemplares similares
-
Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth
por: Das, Amlan, et al.
Publicado: (2017) -
Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway
por: Haque, Inamul, et al.
Publicado: (2018) -
Pancreatic Tumor Cell Secreted CCN1/Cyr61 Promotes Endothelial cell migration and Aberrant Neovascularization
por: Maity, Gargi, et al.
Publicado: (2014) -
Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis
por: Haque, Inamul, et al.
Publicado: (2011) -
Cyr61/CCN1 targets for chemosensitization in pancreatic cancer
por: Banerjee, Snigdha, et al.
Publicado: (2019)